Pharmaron Beijing Co., Ltd., together with its subsidiaries, provides drug research and development, and production services to the life sciences industry in North America, Europe, Japan, Mainland China, rest of Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Preparation Process Development, and Production Services; Clinical Research Services; Macromolecule and Cell, and Gene Therapy Services; and Others. The company offers laboratory chemical services, including medicinal chemistry, synthetic chemistry, analytical and purification chemistry, and computer-aided drug design; bioscience services, such as in vitro and in vivo drug metabolism and pharmacokinetics, in vitro biology and in vivo pharmacology, drug safety evaluation, and US laboratory services; and process development and production, material science/preparation, preparation development and production, and analytical development services. It also provides radiolabeling science and early clinical trial services; clinical trial and clinical research site management services; and macromolecular drug discovery and development, and production services (CDMO), as well as cell and gene therapy laboratory, and gene therapy CDMO services. In addition, the company provides safety assessment, and chemistry, manufacturing, and controls services. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
Stock data | 2024 | Change |
---|---|---|
Price | $2.75 | N/A |
Market Cap | $4.08B | N/A |
Shares Outstanding | 1.49B | N/A |
Employees | 19.48K | N/A |